| 產品編號 | bs-12512R |
| 英文名稱 | Rabbit Anti-ARFBP1 antibody |
| 中文名稱 | ADP核糖基化因子結合蛋白抗體 |
| 別 名 | ARF binding protein 1; ARF BP1; ARF-binding protein 1; ARF-BP1; BJ-HCC-24 tumor antigen; E3 ubiquitin protein ligase HUWE1; E3 ubiquitin-protein ligase HUWE1; HECT; HECT domain protein LASU1; HECT UBA and WWE domain containing protein 1; HectH9; Homologous to E6AP carboxyl terminus homologous protein 9; HUWE; Huwe1; HUWE1_HUMAN; Ib772; KIAA0312; KIAA1578; Large structure of UREB1; LASU1; Mcl 1 ubiquitin ligase E3; Mcl-1 ubiquitin ligase E3; MULE; UBA and WWE domain-containing protein 1; Upstream regulatory element-binding protein 1; URE B1; URE-B1; URE-binding protein 1; UREB 1; UREB1. |
 |
Specific References (2) | bs-12512R has been referenced in 2 publications.
[IF=9.727] Chen Y et al. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53. Cancer Res. 2020 Jun 1;80(11):2175-2189. WB ; Human.
[IF=8.378] Chen Y et al. Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53. Cancer Res. 2020 Feb 17. pii: canres.1912.2019. WB ; Human.
|
| 研究領域 | 細胞生物 信號轉導 轉運蛋白 泛素 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human,Mouse,Rat,Rabbit,Pig,Sheep,Cow,Dog,Horse) |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 482kDa |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ARF6: 3201-3400/43741 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1. Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair. Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4. Binds to an upstream initiator-like sequence in the preprodynorphin gene. Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN. May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation. Function: GTP-binding protein involved in protein trafficking; regulates endocytic recycling and cytoskeleton remodeling. May modulate vesicle budding and uncoating within the Golgi apparatus. Functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in the regulation of dendritic spine development (By similarity). Contributes to the regulation of dendritic branching and filopodia extension. Subunit: Interacts with isoform p14ARF of CDKN2A which strongly inhibits HUWE1 ubiquitin ligase activity. Interacts with MYCN, POLB and CDC6. Subcellular Location: Cytoplasm. Nucleus. Mainly expressed in the cytoplasm of most tissues, except in the nucleus of spermatogonia, primary spermatocytes and neuronal cells (By similarity). Predominantly cytosolic or perinuclear in some colorectal carcinoma cells. Tissue Specificity: Weakly expressed in heart, brain and placenta but not in other tissues. Expressed in a number of cell lines, predominantly in those from colorectal carcinomas. Post-translational modifications: Phosphorylated on tyrosine; phosphorylation is probably required for its ability to inhibit TP53 transactivation. Phosphorylated upon DNA damage, probably by ATM or ATR. DISEASE: Defects in HUWE1 are the cause of mental retardation syndromic X-linked Turner type (MRXST) [MIM:300706]; also known as mental retardation and macrocephaly syndrome. MRXST shows clinical variability. Associated phenotypes include macrocephaly and variable contractures. A chromosomal microduplication involving HUWE1 and HSD17B10 is the cause of mental retardation X-linked type 17 (MRX17) [MIM:300705]; also known as mental retardation X-linked type 31 (MRX31). Mental retardation is characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. In contrast to syndromic or specific X-linked mental retardation which also present with associated physical, neurological and/or psychiatric manifestations, intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation. Similarity: Belongs to the TOM1/PTR1 family. Contains 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain. Contains 1 UBA domain. Contains 1 UIM (ubiquitin-interacting motif) repeat. Contains 1 WWE domain. SWISS: Q7Z6Z7 Gene ID: 10075 Database links: Entrez Gene: 465650 Chimpanzee Entrez Gene: 10075 Human Entrez Gene: 59026 Mouse SwissProt: Q7Z6Z7 Human SwissProt: Q5BMM7 Mouse SwissProt: Q7TMY8 Mouse Unigene: 136905 Human Unigene: 27372 Mouse |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
